China Medical Insurance Research Association: The total annual procurement volume of unselected original research drugs in the country fell by an average of 46%

Per reporter Li Biao intern reporter Cai Zhichao Beijing photography report per editor Chen Xing

On December 15, China Medical Insurance magazine held a press conference on "Changes in the Use of Original Research Drugs Selected in The Collection".

The "Daily Economic News" reporter noted at the press conference site that Hu Xin, the chief pharmacist of the Pharmacy Department of Beijing Hospital, based on the data of the hospital, explained that the collection not only significantly reduced the cost of drugs for diabetes, hepatitis B and other diseases, but also greatly improved the accessibility of drugs and realized the replacement of generic drugs for the original drugs.

At the same time, Hu Xin stressed that according to the efficacy and safety evaluation results of the data in the real diagnosis and treatment environment, there was no difference in clinical efficacy and safety between 14 selected generic drugs in 8 treatment areas such as hepatitis B, hypertension and tumors, which provided important evidence-based medical evidence for generic drugs to replace original research drugs.

The purchase of unselected original research drugs has decreased significantly

The national drug collection has been carried out for more than 3 years, and the situation of not selecting the original research drugs has always been a hot spot of concern to the outside world.

Liu Wenxin, director of the technical standards department of the China Medical Insurance Research Association, said at the meeting that the purchase volume of unselected original research drugs has been greatly reduced, and the "substitution effect" of selected generic drugs on the original drugs that have not been selected is obvious. One year after the implementation of the collection results, the total annual procurement volume of the original research drugs that were not selected decreased by an average of 46% compared with the year before the implementation of the collection results.

Among them, simvastatin oral regular-release doses decreased the most, reaching 74.4%; followed by aluminum magnesium carbonate chewable tablets, with a decrease of 60.3%; again, valsartan oral regular-release dosage forms, a decrease of 55%; and imatinib oral long-release dosage forms with the least reduction, also reached 13.4%.

The purchase volume of unselected generic drugs has dropped more, and the "substitution effect" of "high-quality and affordable" selected generic drugs on unselected generic drugs is also obvious. Liu Wenxin said that the total annual procurement volume of unselected generic drugs fell by 80.8%, 9 drugs fell by more than 70%, and 6 were more than 80%. Among them, atorvastatin oral regular-release dosage form decreased the most, reaching 94.9%.

In addition, the procurement volume of selected generic drugs has risen sharply; the procurement volume of 9 drugs according to the generic name has continued to rise, the amount effect is significant, and the masses who cannot afford to use the corresponding drugs in the past have used drugs, and hospitals are more inclined to provide drugs for collection; the collection policy promotes the optimization of the drug use structure.

Under the same generic name, the original research drugs, the selected generic drugs and the unselected generic drugs have "dropped in three prices", and the burden of medication for the masses has been significantly reduced.

Liu Wenxin concluded that first of all, in terms of generic names, the average price of 9 drugs has decreased significantly, with an average decrease of 67.1%. Secondly, the price decline of the selected generic drugs is the most significant. The effect of "exchanging price for volume" is obvious, and the average price of the 9 selected generic drugs has dropped by 82.4%.

At the same time, Liu Wenxin also said that the prices of original research drugs and unselected generic drugs have dropped with the trend. According to the decline in the price of the selected generic drugs, the medical insurance departments in various places have jointly lowered the price of the corresponding non-selected original research drugs, or anchored the lowest price in the country, or anchored the Purchase Price in Shanghai, guiding the price of the original research drugs of the non-selected original research drugs to decline. The average reduction rate of the 9 unselected generic drugs was 17.4%.

After the drug collection, the "patent cliff" has emerged

Jiang Changsong, director of the Price Recruitment Office of the National Medical Security Research Institute, introduced that from the perspective of the drug use in developed countries such as Europe, the United States and Japan, the market structure of prescription drugs is generally 20% of the number of patented drugs, and the amount accounts for 80%. However, the situation before the collection in China is that the number of domestic generic drugs accounts for 80%, and the amount accounts for only 20%, and it has not formed an effective "patent cliff".

The "Daily Economic News" reporter learned that the "patent cliff" of the pharmaceutical industry refers to the phenomenon that when the original research drug expires its patent protection, the generic drug will enter and occupy the market at a lower price, resulting in a significant decline in the market share or interests of the original research drug.

Jiang Changsong then said that the current procurement model adopted in China is the most effective drug procurement model in line with China's national conditions. An important mechanism of this model is to exchange volume for price through volume procurement. Since the launch of centralized drug procurement, the lowest unit price of drugs has decreased by more than 40%, and the highest has also decreased by more than 90%, and there is obviously a "patent cliff".

Some doctor representatives believe that the collection promotes generic drugs to replace the original research drugs, further stabilizes the quality of generic drugs, reduces the price of commonly used drugs, improves patient medication compliance, reduces the economic burden of patients, and improves the health level of patients. At the same time, a number of enterprises are allowed to win the bid to ensure the supply of winning products. In addition, measures such as prepayment of funds and retention of balances to medical institutions have increased the enthusiasm of medical institutions to participate in collection.

The patient representative said that before the implementation of the drug collection results, patients and their families shouldered a high burden of medical costs, with the promotion of centralized drug procurement, the selected generic drugs not only dropped sharply in price, but also the efficacy was also very stable, after taking the body feeling and various indicators are no less than taking the original research drugs, so that patients can rest assured that the drug, the burden is reduced.

Daily economic news